Items where authors include "James, ND"

Export as [feed] Atom [feed] RSS
Jump to: Article
Number of items: 7.

Article

James, ND, Liu, W, Pirrie, S et al. (19 more authors) (2022) TUXEDO: a phase I/II trial of cetuximab with chemoradiotherapy in muscle‐invasive bladder cancer. BJU International. ISSN 1464-4096

Parker, CC, James, ND, Brawley, CD et al. (43 more authors) (2022) Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. PLOS Medicine, 19 (6). e1003998. ISSN 1549-1277

Hussain, SA, Lester, JF, Jackson, R et al. (17 more authors) (2022) Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. The Lancet Oncology, 23 (5). pp. 650-658. ISSN 1213-9432

Llewellyn, MA, Gordon, NS, Abbotts, B et al. (8 more authors) (2018) Defining the frequency of human papillomavirus and polyomavirus infection in urothelial bladder tumours. Scientific Reports, 8 (1). 11290. ISSN 2045-2322

Snell, KIE, Ward, DG, Gordon, NS et al. (7 more authors) (2018) Exploring the roles of urinary HAI-1, EpCAM & EGFR in bladder cancer prognosis & risk stratification. Oncotarget, 9 (38). pp. 25244-25253.

Ambrose, SR, Gordon, NS, Goldsmith, JC et al. (6 more authors) (2015) Use of Aleuria alantia Lectin Affinity Chromatography to Enrich Candidate Biomarkers from the Urine of Patients with Bladder Cancer. Proteomes, 3 (3). 266 - 282. ISSN 2227-7382

Bryan, RT, Regan, HL, Pirrie, SJ et al. (6 more authors) (2015) Protein shedding in urothelial bladder cancer: Prognostic implications of soluble urinary EGFR and EpCAM. British Journal of Cancer, 112 (6). 1052 - 1058. ISSN 0007-0920

This list was generated on Sat Mar 23 23:30:39 2024 GMT.